Elevated plasma hepcidin concentrations are associated with an increased risk of mortality and nonfatal cardiovascular events in patients with type 2 diabetes: A prospective study
Elevated plasma hepcidin concentrations are associated with an increased risk of mortality and nonfatal cardiovascular events in patients with type 2 diabetes: A prospective study
Background: The effect of plasma hepcidin concentrations on the long-term risk of developing adverse cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM) is unclear.
Methods: We followed for a median of 55.6 months 213 outpatients with established T2DM (45.5% women, mean age 69 ± 10 years; BMI 28.7 ± 4.7 kg/m2; median diabetes duration 11 years). Baseline plasma ferritin and hepcidin concentrations were measured with an electrochemiluminescence immunoassay and mass spectrometry-based assay, respectively. The primary study outcome was a composite of all-cause mortality or incident nonfatal cardiovascular events (inclusive of myocardial infarction, permanent atrial fibrillation, ischemic stroke, or new hospitalization for heart failure).
Results: 42 patients developed the primary composite outcome over a median follow-up of 55.6 months. After stratifying patients by baseline hepcidin tertiles [1st tertile: median hepcidin 1.04 (IQR 0.50-1.95) nmol/L, 2nd tertile: 3.81 (IQR 3.01-4-42) nmol/L and 3rd tertile: 7.72 (IQR 6.37-10.4) nmol/L], the risk of developing the primary composite outcome in patients in the 3rd tertile was double that of patients in the 1st and 2nd tertile combined (unadjusted hazard ratio [HR] 2.32, 95%CI 1.27-4.26; p = 0.007). This risk was not attenuated after adjustment for age, sex, adiposity measures, smoking, hypertension, statin use, antiplatelet medication use, plasma hs-C-reactive protein and ferritin concentrations (adjusted HR 2.53, 95%CI 1.27-5.03; p = 0.008).
Conclusions: In outpatients with T2DM, higher baseline hepcidin concentrations were strongly associated with an increased long-term risk of overall mortality or nonfatal cardiovascular events, even after adjustment for established cardiovascular risk factors, plasma ferritin concentrations, medication use, and other potential confounders.
305
Mantovani, Alessandro
311fe4fb-501a-458c-a1b8-5133167beb4e
Busti, Fabiana
85167efe-ee5b-40d6-bfb8-5705dafda137
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c
17 August 2024
Mantovani, Alessandro
311fe4fb-501a-458c-a1b8-5133167beb4e
Busti, Fabiana
85167efe-ee5b-40d6-bfb8-5705dafda137
Byrne, Chris
1370b997-cead-4229-83a7-53301ed2a43c
Byrne, Chris
,
et al.
(2024)
Elevated plasma hepcidin concentrations are associated with an increased risk of mortality and nonfatal cardiovascular events in patients with type 2 diabetes: A prospective study.
Cardiovascular Diabetology, 23 (1), , [305].
(doi:10.1186/s12933-024-02377-x).
Abstract
Background: The effect of plasma hepcidin concentrations on the long-term risk of developing adverse cardiovascular outcomes in people with type 2 diabetes mellitus (T2DM) is unclear.
Methods: We followed for a median of 55.6 months 213 outpatients with established T2DM (45.5% women, mean age 69 ± 10 years; BMI 28.7 ± 4.7 kg/m2; median diabetes duration 11 years). Baseline plasma ferritin and hepcidin concentrations were measured with an electrochemiluminescence immunoassay and mass spectrometry-based assay, respectively. The primary study outcome was a composite of all-cause mortality or incident nonfatal cardiovascular events (inclusive of myocardial infarction, permanent atrial fibrillation, ischemic stroke, or new hospitalization for heart failure).
Results: 42 patients developed the primary composite outcome over a median follow-up of 55.6 months. After stratifying patients by baseline hepcidin tertiles [1st tertile: median hepcidin 1.04 (IQR 0.50-1.95) nmol/L, 2nd tertile: 3.81 (IQR 3.01-4-42) nmol/L and 3rd tertile: 7.72 (IQR 6.37-10.4) nmol/L], the risk of developing the primary composite outcome in patients in the 3rd tertile was double that of patients in the 1st and 2nd tertile combined (unadjusted hazard ratio [HR] 2.32, 95%CI 1.27-4.26; p = 0.007). This risk was not attenuated after adjustment for age, sex, adiposity measures, smoking, hypertension, statin use, antiplatelet medication use, plasma hs-C-reactive protein and ferritin concentrations (adjusted HR 2.53, 95%CI 1.27-5.03; p = 0.008).
Conclusions: In outpatients with T2DM, higher baseline hepcidin concentrations were strongly associated with an increased long-term risk of overall mortality or nonfatal cardiovascular events, even after adjustment for established cardiovascular risk factors, plasma ferritin concentrations, medication use, and other potential confounders.
Text
Hepcidin_cardiovascular events in T2DM_R1_highlighted
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
Image
Figure 1
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
Image
Figure 2
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
Image
Figure S1
- Accepted Manuscript
Restricted to Repository staff only
Request a copy
Text
s12933-024-02377-x
- Version of Record
Show all 5 downloads.
More information
Accepted/In Press date: 25 July 2024
Published date: 17 August 2024
Additional Information:
Please check journal restrictions on embargo etc
Identifiers
Local EPrints ID: 493202
URI: http://eprints.soton.ac.uk/id/eprint/493202
ISSN: 1475-2840
PURE UUID: 8981ac8b-bf9c-4a29-a396-45ccb3bb9b32
Catalogue record
Date deposited: 27 Aug 2024 17:30
Last modified: 30 Aug 2024 01:36
Export record
Altmetrics
Contributors
Author:
Alessandro Mantovani
Author:
Fabiana Busti
Corporate Author: et al.
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics